Kornimate/medical-research-clean huggingface dataset:
pirfenidone lp or collagen-polyvinylpyrrolidone in covid-19

Conditions: COVID 19

Summary: collagen-polyvinylpyrrolidone (collagen-pvp) and pirfenidone have the ability to control cytokine storms. this work explores the therapeutic effects of both, on the early treatment of patients with severe covid-19. the hospital stay, quick covid-19 severity index (qcsi) and admission to the icu were statistically significantly lower when the patients were treated with collagen-pvp or pirfenidone, compared to the controls treated with dexamethasone alone.

the therapeutic target of covid-19 is focused on the control of inflammation and the prevention of fibrosis. collagen-polyvinylpyrrolidone (collagen-pvp) and pirfenidone have the ability to control cytokine storms observed in rheumatic and fibrotic disorders. in this work, the investigators explored the therapeutic effects of both, in addition to dexamethasone, on the early treatment of patients with severe covid-19. the hospital stay, quick covid-19 severity index (qcsi) and admission to the icu were statistically significantly lower when the patients were treated with collagen-pvp or pirfenidone, compared to the controls treated with dexamethasone alone. furthermore, only collagen-pvp normalized serum glucose at discharge. since the intracellular mechanism of action of pirfenidone is partially known, it was performed a whole human genome microarray assay with total rna isolated from fibroblast and macrophage cultures treated with collagen-pvp. ingenuity pathway analysis showed that cell cycle, inflammation, and cell surface-extracellular matrix interaction could be regulated by the collagen-pvp copolymer, by down-regulation of pro-inflammatory cytokines, such as il-6 and -8, while th2 anti-inflammatory response signaling could be up-regulated. additionally, down-regulation of some of the genes involved in nitric oxide production by inducible nitric oxide synthase showed a possible control for jak, in the ifn-γ pathway, allowing the possibility of controlling inflammation through the jak/stat pathway, as has been observed for pirfenidone and other immunomodulators, such as ruxolitinib. in summary, once again, collagen-pvp and pirfenidone have demonstrated to favor inflammatory control and stand out as a possible therapy for inflammatory disorders derived from viral or microorganism infections.

Eligibility criteria:
inclusion criteria: * patients infected with sars-cov-2, hospitalized, with total bilirubin ≤1.5 exclusion criteria: * if the patient underwent treatment with biological antirheumatic drugs, disease modifiers (dmards) or other immunosuppressive agents, patients who required continuous therapy with systemic corticosteroids in a dose greater than 10 mg of prednisone per day or equivalent; pregnant women, calculated creatinine clearance (or estimated glomerular filtration rate less than 10 ml/min or patients requiring renal replacement therapy

Keywords: collagen-polyvinylpyrrolidone pirfenidone survival immunomodulation
efficacy of treatment with pramipexole or risperidone in patients with refractory obsessive-compulsive disorder (ocd)

Conditions: Obsessive-Compulsive Disorder

Summary: this is a phase 2, randomized, controlled clinical trial to study the efficacy of pramipexol or risperidone in the treatment of refractory odc patients. this study is a two-parallel-group clinical trial with duration of 28 weeks (recruitment phase, 4 weeks + treatment phase, 16 weeks + follow-up phase, 8 weeks. the primary endpoint of this study is the score in the y-bocs scale measured between baseline and eot ( at week 16).


Eligibility criteria:
inclusion criteria: 1. age between 18 and 64 years; 2. european portuguese as mother tongue; 3. patients diagnosed with ocd, regardless of subtype, according to dsm-5 and/or icd-10 criteria; 4. yale-brown obsessive compulsive scale (y-bocs) score ≥ 16; 5. patients who do not respond to treatment with at least two selective serotonin reuptake inhibitor antidepressants (ssris) at the maximum tolerated therapeutic dose with or without psychotherapy, i.e. patients in whom there is no reduction in the y-bocs score by 25% to 35% relative to the score obtained before starting treatment with ssris (rauch \& jenike, 1994). exclusion criteria: 1. patients who have a complete response to drug treatment with or without psychotherapy, i.e. patients with a reduction in y-bocs score by 25% to 35% regarding the score obtained before starting treatment with ssris (rauch \& jenike, 1994); 2. patients with current or anterior history of psychotic illness (schizophrenia, delusions, among others); 3. patients with bipolar disorder; 4. patients with tick disorder; 5. patients with borderline personality disorder; 6. patients with social anxiety disorder; 7. patients with current or anterior history of dietary behavior disorders (at least in the last 6 months); 8. patients with a history of neurological disease or traumatic brain injury; 9. patients with history of alcohol abuse or illicit substances (at least in the last 6 months); 10. patients who are passing or have passed in the last 6 months by a major depressive episode; 11. patients that undergo deep brain stimulation; 12. presence of sensory deficits impeding participation in clinical study; 13. pregnant or in breastfeeding period; 14. patients doing medication or receiving prohibited treatments; 15. patients with contraindication to perform mri.
relationship between liver cancer and sarcopenia

Conditions: Liver Cancer; Sarcopenia

Summary: by tracking the short-term and long-term results of patients after hepatectomy, the difference of short-term results between patients with sarcopenia and patients without sarcopenia was analyzed, and the correlation between sarcopenia and short-term and long-term results of patients after hepatectomy was explored, so as to improve people's awareness of sarcopenia and pay attention to its prevention and treatment.

all implementation details are based on the newest ewgsop definition. the investigators consecutively admitted patients the questionnaire and evaluated the assessment of muscle strength (grip strength test and chair stand test), muscle quantity (l3 plane total skeletal muscle area) and physical performance (gait test) following the f-a-c-s approach, to confirm patients with sarcopenia accurately. and by tracking the short-term and long-term outcomes of patients after hepatectomy, the differences were analyzed and the relationship between sarcopenia and liver cancer was explored.

Eligibility criteria:
inclusion criteria: * patients with preoperative clinical diagnosis of liver cancer * no cancer other than liver cancer has been diagnosed * age ≥18 years exclusion criteria: * patients who could not complete the standard tests and questionnaires * patients who did not accept liver resection after evaluation of treatment plan * patients who had other concomitant preoperative causes of muscle weakness (injury, fracture, stroke, etc.) * patients who missing ct data or ct scan did not reach the level of the third lumbar vertebra (l3)

Keywords: sarcopenia liver cancer hepatectomy short-term outcomes long-term outcomes
analysis of blood and bone marrow to detect residual disease in patients with previously treated hairy cell leukemia

Conditions: Leukemia

Summary: rationale: diagnostic procedures that detect residual disease may predict disease relapse in patients who have hairy cell leukemia. purpose: diagnostic trial to determine the effectiveness of analyzing blood and bone marrow to detect residual disease in patients who have previously treated hairy cell leukemia.

objectives: i. compare the sensitivity of flow cytometry, immunohistochemistry, and polymerase chain reaction in detecting minimal residual disease following therapy with cladribine in patients with hairy cell leukemia. outline: blood and bone marrow samples are obtained from patients at time of bone marrow biopsies to assess minimal residual disease using flow cytometry, immunohistochemistry, and polymerase chain reaction. patients are followed for 2 years or until disease relapse. projected accrual: a total of 15 patients will be accrued for this study over 12-24 months.

Eligibility criteria:
disease characteristics: clinically documented hairy cell leukemia active or in remission must have received prior cladribine and be undergoing bone marrow biopsies as follow up patient characteristics: age: over 18 performance status: not specified life expectancy: not specified hematopoietic: not specified hepatic: not specified renal: not specified prior concurrent therapy: biologic therapy: not specified chemotherapy: see disease characteristics no prior chemotherapy following prior cladribine endocrine therapy: not specified radiotherapy: not specified surgery: not specified

Keywords: progressive hairy cell leukemia, initial treatment refractory hairy cell leukemia
a research study looking into blood levels of the medicine nnc0519-0130 in the body in participants with normal or reduced kidney function

Conditions: Diabetes Mellitus, Type 2

Summary: nnc0519-0130 is a new medicine to improve the treatment options for people living with type 2 diabetes and people with overweight. in this study one dose of nnc0519-0130 will be given and blood levels of nnc0519-0130 will be compared between people with reduced kidney function and people with normal kidney function. the study will last up to 52 days including a screening phase of up to 28 days prior to dosing.


Eligibility criteria:
inclusion criteria: * male or female of non-childbearing potential, aged 18-75 years (both inclusive) at the time of signing the informed consent. * body mass index (bmi) between 20.0 and 39.9 kilogram per square metre (kg/m\^2) (both inclusive) at screening. * meeting the pre-defined glomerular filtration rate (gfr) criteria using estimated gfr (egfr) based on the chronic kidney disease epidemiology collaboration (ckd-epi) creatinine equation (2021) adjusted for estimated individual body surface area (bsa) for any of the renal function groups: * for participants with normal renal function: egfr of greater than or equal to 90 millilitres per minute (ml/min) * stage 2: for participants with mild renal impairment: egfr of 60-89 ml/min * stage 3: for participants with moderate renal impairment: egfr of 30-59 ml/min * stage 4: for participants with severe renal impairment: egfr of 15-29 ml/min not requiring dialysis * stage 5: for participants with kidney failure: egfr of less than 15 ml/min and requiring dialysis treatment exclusion criteria: * any disorder which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol. * presence or history of any clinically relevant respiratory, metabolic, renal, hepatic, cardiovascular, gastrointestinal, or endocrinological conditions (except conditions associated with renal impairment or kidney failure) as judged by the investigator. * use of drugs known to affect creatinine clearance including cephalosporin and aminoglycoside, antibiotics, flucytosine, cisplatin, cimetidine, trimethoprim, cibenzoline and nitrofurantoin within 14 days or 5 half-lives, whichever is greater, before planned dosing of the investigational medicinal product (imp).
influence of gum chewing on postoperative bowel activity after complete staging surgery for gynecological malignancies

Conditions: Postoperative Ileus

Summary: postoperative ileus can cause the accumulation of secretions and gas, resulting in nausea, vomiting and abdominal distension and pain. prolonged paralytic ileus is one of the commonest reasons for delayed recovery and discharge from hospital following abdominal surgery. advances in surgical techniques and peri-operative management such as the use of laparoscopic surgery, thoracic epidural analgesia, early postoperative feeding and mobilization, amongst others, have been shown to help in the resolution of postoperative ileus. chewing gum, as a proxy for sham feeding, may accelerate the motility of the gi tract by stimulating the cephalic phase of digestion and eliciting the release of multiple promotility gi hormones. a number of small controlled studies evaluating the effect of chewing gum on postoperative intestinal recovery in patients undergoing colorectal surgery have been conducted. decreased time for bowel function recovery and decreased hospital length of stay have not been consistently documented, possibly owing to the insufficient power of existing studies and study design issues. in addition, all previous studies have been limited by their use of sugarfree gum, containing known motility agents (eg, sorbitol). in this study, gum chewing was studied for its effect on women with surgical staging for malignant gynecologic disease such as endometrial cancer, cervix cancer and ovarian cancer.


Eligibility criteria:
inclusion criteria: * women who would undergo surgical staging for malignant gynecologic disease such as endometrial cancer, cervix cancer and ovarian cancer were assessed for eligibility. exclusion criteria: * women who had thyroid diseases, inflammatory bowel disease, complaints of chronic constipation (defined as two or less bowel movements per week), had a history of prior abdominal bowel surgery, abdominal radiation, or neoadjuvant chemotherapy, * need for intensive care more that 24 hours postoperatively, had nasogastric tube drainage beyond the first postoperative morning bowel anastomosis in relation to their operation during the surgery

Keywords: gynecological malignancies postoperative bowel activity gum chewing
comparison of the effects of weight changes on serum adipokines in patients diagnosed with anorexia nervosa and morbid obesity

Conditions: Anorexia Nervosa; Bariatric Surgery; Weight Change, Body

Summary: in this study, when patients diagnosed with an started treatment and their weight increased by 10%; on the other hand, it was aimed to compare the changes in serum adipokine levels observed in morbidly obese patients before bariatric surgery and when they lost 10% of their post-op weight with both anthropometric measurements, biochemical parameters, and values of healthy volunteers.

the most characteristic feature of obesity is the increase in adipose tissue. on the contrary, in anorexia nervosa, there is a decrease in adipose tissue enough to impair neuroendocrine functions. adipose tissue is formed by loosely binding lipid-filled cells called adipocytes and is now considered an important part of energy metabolism. adipokines it secretes play a role in many physiological processes of the body such as nutrition, appetite, energy balance, insulin, and glucose metabolism, lipid metabolism, regulation of blood pressure, vascular remodeling, coagulation, and inflammation. therefore, changes in the amount of body fat in these two patient groups, which are at the two ends of the spectrum, affect both the biochemical parameters and physiological functions of the patients in different ways. it is expected that both adipokine levels and biochemical parameters will approach the values of healthy subjects with a decrease in adipose tissue of clinically morbidly obese patients and an increase in adipose tissue of patients with an. however, in some studies comparing the parameters of patients with constitutionally weak patients and patients with an, results contrary to expectations were obtained. in this study, we compared the extent to which weight changes changed adipokines and correlated with biochemical parameters based on healthy and normal-weight volunteers.

Eligibility criteria:
inclusion criteria: * for anorexia nervosa group: * have been diagnosed with anorexia nervosa * bmi \<18 kg/m2 * good general health * volunteering to participate in the study * for morbidly obese group: * who was diagnosed with morbid obesity and planned to undergo rygb operation * bmi\> 40 kg/m2 * volunteering to participate in the study * for healthy volunteers: * good general health * bmi \>20 and \<30 kg/m2 * volunteering to participate in the study exclusion criteria: * \ 60 years old * to had type 2 diabetes, hypertension, liver and kidney failure, cancer, or a chronic disease

Keywords: adipocytokines leptin adiponectin omentin apelin il-6 anorexia nervosa bariatric surgery fat mass
risk of hospitalization for severe hypersensitivity (including severe skin reactions) in patients with type 2 diabetes exposed to oral antidiabetic treatments

Conditions: Diabetes Mellitus, Type 2

Summary: the purpose of this study is to compare the incidence hospitalization for severe hypersensitivity and cutaneous reactions among patients with type 2 diabetes who are new users of saxagliptin and those who are new users of other oral antidiabetic drugs.

prospectively designed retrospective database study. this study will be conducted using administrative claims data and electronic medical records that are collected as part of routine clinical practice

Eligibility criteria:
inclusion criteria: * 18 years of age or older * newly prescribed saxagliptin or an oral anti-diabetic drug (oad) in a class other than dipeptidyl peptidase iv (dpp4) inhibitors * enrolled in the respective database for at least 180 days prior to first prescription of new oad * have at least one diagnostic code for a type 2 diabetes-related condition exclusion criteria: * patients with an inpatient diagnostic code for any of the conditions of interest within the 180-day baseline period * patients prescribed a dpp4 inhibitor during the baseline period
pregnancy in women with rare multisystemic vascular diseases: cograre5 study

Conditions: Vascular Anomaly; Osler Rendu Disease; Marfan Syndrome or Related; Lymphedema Primary; Arteriovenous Malformations; Cerebrospinal; Disorder

Summary: there are no prospective studies of pregnancies for the diseases studied here in (heredity hemorrhagic telangiectasia, marfan syndrome or related, primary lower limb lymphedema, superficial arteriovenous malformations, and cerebro-spinal arteriovenous malformations) although complications of these can present life-threatening health problems for the mother and her baby. the purpose of this national prospective study is to obtain greater insight into obstetrical complications associated with rare maternal vascular genetic disorders in order to improve prevention and to reduce risk of death. in this context, experts and patient associations consider that there is a need to make real progress in the formulation of recommendations based on scientific data.


Eligibility criteria:
inclusion criteria: * women aged ≥ 18 years and ≤45 years at the time of inclusion * pregnant and/or having given birth less than 1 month (≤ 30 days) * clinically and/or radiological and/or molecular biology diagnosis of a rare vascular disease before or during pregnancy or one month after delivery. * having been informed of all pertinent aspects of the study and provided oral non-opposition. exclusion criteria: * any person not fulfilling the inclusion criteria or refusing to take part in the study. * major under legal protection
difficult encounters in pain medicine

Conditions: Chronic Pain

Summary: the investigators are seeking to determine factors associated with difficult patient encounters in an academic pain clinic. the investigators are examining 36 different variables to determine the association with "difficult" patient encounters as independently rated by a trainee and attending physician.

pain is associated with significant psychosocial pathology include axis 1 diagnoses, opioid use and misuse, unemployment, and strained relationships, and treatments for chronic pain are often ineffective. collectively, these factors may result in a higher prevalence of patients characterized as 'difficult', which can lead to missed diagnoses, barriers to care resulting in poorer outcomes (professional pessimism, mistrust, passive treatment, referrals to other providers or discharge), patient complaints and 'hero' events, avoidable legal claims, and increased risk of professional burnout. characterizing patients as "difficult" (instead of encounters) may have negative consequences for future care, and there are few studies that have explored patients' perspectives on "difficult" encounters. although several articles have narratively explored this issue, there are few targeted at chronic pain patients, and no studies in this population that set out to determine what variables are associated with a "difficult encounter", the congruence between patients' and providers' impressions of an encounter, or whether difficult encounters are associated with pain treatment outcome.

Eligibility criteria:
inclusion criteria: * ≥ 18 years of age * pain duration \> 3 months * new visit (or no visit within 3 years) exclusion criteria: * referral only for diagnostic procedure * friend or relative, or direct referral from friend or relative

Keywords: chronic pain
short-term effects of dynamic taping in patients with lumbar disc herniation

Conditions: Lumbar Disc Herniation; Acute Pain

Summary: previous evidence has shown that kinesio tape application reduces pain levels and improves disability in patients with chronic low back pain due to lumbar disc herniation. however, it is not known, whether the dynamic taping can decrease back pain, improve endurance of paraspinal muscles, and improve functional capacity in patients with lumbar disk herniation. the aim of the current study is to examine the acute effects of dynamic taping on pain, pain threshold, endurance, balance, lumbar joint mobility and functionality in patients with lumbar disc herniation.

the study will include 34 volunteer adult patients who have been diagnosed with lumbar disc herniation according to the physical examination and magnetic resonance imaging and have referred to the physiotherapy and rehabilitation service by a specialist physician. the patients will be divided into 2 groups as dynamic tape (n=17) and sham tape (n=17). patients' pain will be evaluated with numerical rating scale, pain threshold jtech commander digital algometer, lumbar muscle endurance modified sorenson test, balance functional reach test, lumbar joint mobility universal goniometer and functional movement levels of patients with timed get up and go test. evaluations will be carried out in 3 stages: before taping, 2 hours after taping and 3 days after taping. the measurements of the dynamic and sham taping applications of the 2 hours after and 3 days will be compared with the pre-taping and post taping results between two groups. the outcomes of the study will be analyzed by appropriate statistical methods.

Eligibility criteria:
inclusion criteria: * patients with diagnose of lumbar disc herniation, * self-reported activity pain due to lumbar disc herniation for at least the last 3 months, * with pain severity equal to or greater than 3 on a numerical rating scale, * patients with no skin irritation, sensitivities or allergies exclusion criteria: * patients with spinal pathology, lumbar surgery, motor weakness, urinary or fecal incontinence due to lumbar disc herniation, cauda equina syndrome, pregnancy, neurological or rheumatological condition, dermatitis or pre-existing skin lesion over the taping area, and having dynamic taping allergies

Keywords: lumbar disc herniation dynamic tape acute pain